Anna Korycka

1.0k total citations
51 papers, 781 citations indexed

About

Anna Korycka is a scholar working on Genetics, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Anna Korycka has authored 51 papers receiving a total of 781 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 18 papers in Public Health, Environmental and Occupational Health and 17 papers in Hematology. Recurrent topics in Anna Korycka's work include Chronic Lymphocytic Leukemia Research (31 papers), Acute Lymphoblastic Leukemia research (18 papers) and Lymphoma Diagnosis and Treatment (14 papers). Anna Korycka is often cited by papers focused on Chronic Lymphocytic Leukemia Research (31 papers), Acute Lymphoblastic Leukemia research (18 papers) and Lymphoma Diagnosis and Treatment (14 papers). Anna Korycka collaborates with scholars based in Poland, United States and Italy. Anna Korycka's co-authors include Tadeusz Robak, Ewa Lech‐Marańda, Ewa Robak, Piotr Smolewski, Jerzy Z. Błoński, Dariusz Wołowiec, Paweł Robak, Michał Plewka, Jarosław D. Kasprzak and Maria Krzemińska‐Pakuła and has published in prestigious journals such as The American Journal of Cardiology, Molecules and Current Medicinal Chemistry.

In The Last Decade

Anna Korycka

49 papers receiving 760 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Korycka Poland 17 338 304 162 144 114 51 781
Yuri Kamitsuji Japan 16 294 0.9× 369 1.2× 449 2.8× 108 0.8× 223 2.0× 32 929
Andrey Sudarikov Russia 12 157 0.5× 286 0.9× 111 0.7× 136 0.9× 88 0.8× 131 611
Takaaki Ono Japan 14 159 0.5× 312 1.0× 328 2.0× 63 0.4× 215 1.9× 64 691
Mark Bishton United Kingdom 20 214 0.6× 686 2.3× 209 1.3× 477 3.3× 507 4.4× 71 1.3k
Timothy J. Hoy United Kingdom 19 374 1.1× 504 1.7× 189 1.2× 157 1.1× 240 2.1× 34 896
Balcerzak Sp United States 16 244 0.7× 374 1.2× 430 2.7× 138 1.0× 301 2.6× 32 1.0k
Kourosh Lotfi Sweden 18 283 0.8× 400 1.3× 383 2.4× 71 0.5× 264 2.3× 54 968
Christopher M. Sheth United States 9 105 0.3× 306 1.0× 249 1.5× 46 0.3× 194 1.7× 11 791
Monica Pallis United Kingdom 23 168 0.5× 674 2.2× 590 3.6× 63 0.4× 509 4.5× 61 1.3k
Chun Qiao China 15 322 1.0× 318 1.0× 353 2.2× 179 1.2× 159 1.4× 100 825

Countries citing papers authored by Anna Korycka

Since Specialization
Citations

This map shows the geographic impact of Anna Korycka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Korycka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Korycka more than expected).

Fields of papers citing papers by Anna Korycka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Korycka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Korycka. The network helps show where Anna Korycka may publish in the future.

Co-authorship network of co-authors of Anna Korycka

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Korycka. A scholar is included among the top collaborators of Anna Korycka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Korycka. Anna Korycka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Korycka, Anna, Dariusz Wołowiec, Hanna Ławnicka, & Tadeusz Robak. (2025). Assessing adverse event burden in chronic lymphocytic leukemia treatment regimens: what’s best for patient quality of life?. Expert Opinion on Drug Safety. 24(6). 643–655. 2 indexed citations
3.
Korycka, Anna, Dariusz Wołowiec, & Tadeusz Robak. (2016). The safety profile of monoclonal antibodies for chronic lymphocytic leukemia. Expert Opinion on Drug Safety. 16(2). 1–17. 4 indexed citations
4.
Korycka, Anna, Dariusz Wołowiec, & Tadeusz Robak. (2015). Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly. Expert Opinion on Drug Metabolism & Toxicology. 11(9). 1371–1391. 6 indexed citations
5.
Wołowiec, Dariusz, Barbara Cebula‐Obrzut, Jerzy Z. Błoński, et al.. (2014). Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro. Postępy Higieny i Medycyny Doświadczalnej. 68. 1433–1443. 2 indexed citations
6.
Smolewski, Piotr, Magdalena Witkowska, & Anna Korycka. (2013). New Insights into Biology, Prognostic Factors, and Current Therapeutic Strategies in Chronic Lymphocytic Leukemia. ISRN Oncology. 2013. 1–7. 18 indexed citations
7.
8.
Korycka, Anna & Tadeusz Robak. (2012). Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opinion on Drug Metabolism & Toxicology. 8(11). 1455–1468. 11 indexed citations
9.
Franiak‐Pietryga, Ida, et al.. (2012). Type of serum influences the rituximab dependent cytotoxicity and apoptosis of chronic lymphocytic leukemia cells in vitro. Postępy Higieny i Medycyny Doświadczalnej. 66. 730–738. 5 indexed citations
10.
Lech‐Marańda, Ewa, Anna Korycka, & Tadeusz Robak. (2009). Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity. Mini-Reviews in Medicinal Chemistry. 9(7). 805–812. 19 indexed citations
11.
Korycka, Anna, Ewa Lech‐Marańda, & Tadeusz Robak. (2008). Novel Purine Nucleoside Analogues for Hematological Malignancies. Recent Patents on Anti-Cancer Drug Discovery. 3(2). 123–136. 22 indexed citations
12.
Lech‐Marańda, Ewa, Anna Korycka, & Tadeusz Robak. (2006). Pharmacological and Clinical Studies on Purine Nucleoside Analogs- New Anticancer Agents. Mini-Reviews in Medicinal Chemistry. 6(5). 575–581. 27 indexed citations
13.
Robak, Tadeusz, Ewa Lech‐Marańda, Anna Korycka, & Ewa Robak. (2006). Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity. Current Medicinal Chemistry. 13(26). 3165–3189. 111 indexed citations
14.
Korycka, Anna, Piotr Smolewski, & Tadeusz Robak. (2004). The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. European Journal Of Haematology. 73(6). 418–426. 18 indexed citations
15.
Robak, Tadeusz, Anna Szmigielska‐Kapłon, Piotr Smolewski, et al.. (2003). Hodgkin's Type of Richter's Syndrome in Familial Chronic Lymphocytic Leukemia Treated with Cladribine and Cyclophosphamide. Leukemia & lymphoma. 44(5). 859–866. 17 indexed citations
16.
Robak, Tadeusz, H Urbańska-Ryś, Joanna Góra‐Tybor, et al.. (2003). Coexistence of Chronic Lymphocytic Leukemia and Essential Thrombocythemia. Leukemia & lymphoma. 44(8). 1425–1431. 9 indexed citations
17.
Lech‐Marańda, Ewa, Anna Korycka, & Tadeusz Robak. (2000). Influence of gemcitabine (2′,2′‐difluoro‐deoxycytidine) and 2‐chlorodeoxyadenosine on growth of normal and leukemic cellsin vitro. European Journal Of Haematology. 65(5). 317–321. 8 indexed citations
18.
19.
Robak, Tadeusz, Anna Korycka, & Joanna Góra‐Tybor. (1994). The interaction of 2-chlorodeoxy adenosine (2-CDA) and interferon α (IFN-α) on normal and myeloid leukemia hematopoiesis in vitro. Leukemia Research. 18(4). 275–281. 7 indexed citations
20.
Chmielnicka, Jadwiga, et al.. (1993). Comparison of tin and lead toxic action on erythropoietic system in blood and bone marrow of rabbits. Biological Trace Element Research. 36(1). 73–87. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuri Kamitsuji Breakdown of academic impact, for papers by Andrey Sudarikov Breakdown of academic impact, for papers by Takaaki Ono Breakdown of academic impact, for papers by Mark Bishton Breakdown of academic impact, for papers by Timothy J. Hoy Breakdown of academic impact, for papers by Balcerzak Sp Breakdown of academic impact, for papers by Kourosh Lotfi Breakdown of academic impact, for papers by Christopher M. Sheth Breakdown of academic impact, for papers by Monica Pallis Breakdown of academic impact, for papers by Chun Qiao
Rankless by CCL
2026